Marlborough, Mass. –(Newsfile Corp. July 8, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biogeneration company whose gene silencing generation of INTASYL® siRNA is designed to make immune cells more effective at killing tumors. Pittsburgh Cell Oncology (UPMC), today announced the addition of the Department of Dermatology at the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, Pennsylvania, as a clinical trial for its lead product candidate, PH-762.
Phase 1b recently obtained a positive protection recommendation from the Safety Monitoring Committee to increase the dose in the next phase of the Array. The clinical trial is currently enrolling patients for the second cohort.
UPMC’s Department of Dermatology joins four sites involved in the clinical trial: affiliates of the George Washington University School of Medicine in Washington, D. C. ; Banner MD Anderson Cancer Center in Gilbert, Arizona; Clinical Integrity Research Associates in Delray Beach, Florida; and Centricity Research in Dublin, Ohio.
PH-762 is an INTASYL compound that inhibits PD-1, a protein that inhibits the ability of T-motifs to kill cancerous motifs. The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous disease. mobile carcinoma, melanoma or mobile Merkel carcinoma. The test is designed to compare the protection and tolerability of neoadjuvant use of PH-762 injected intratumorally, compare tumor response, and dose or dose diversity for continuation of the PH-762 test. in patients with mobile squamous cell carcinoma, melanoma, or mobile Merkel carcinoma.
More data about this clinical trial can be obtained in clinictrials. gov (identifier: NCT06014086).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biogeneration company whose proprietary INTASYL® siRNA silencing generation is designed to make immune cells more effective at destroying tumor cells. INTASYL is the only generation of self-administered RNAi targeted immuno-oncology. Therapies. INTASYL drugs in particular target expressed proteins that the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Forward-Looking Statements
This press release includes forward-looking announcements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking announcements would likely be referred to by words such as “intends,” “believes,” “anticipates,” “indicates. ” », “plans”, “expects”, “suggests”, “could”, “could”, “should”, “prospective”, “designed for”, “will”, “in progress”, “estimate”, “forecast ” , “target,” “are waiting,” “could” and similar references, although not all forward-looking words imply those words. These words are based solely on our existing beliefs, expectations and assumptions and are subject to inherent uncertainties, threats and threats. adjustments in cases that are difficult to expect and many of which are beyond our control. Examples of forward-looking announcements come with announcements related to the timing, progress and reported understanding of this Phase 1b clinical trial and cure prospects for PH-762. to treat patients with mobile cutaneous squamous cell carcinoma, melanoma or mobile Merkel cancer. Our actual effects would likely differ materially from those indicated in the projections due to a number of vital points, including, but not limited to, The effect on our business and operations of inflationary pressures, higher interest rates, fears of recession, the progression of our product applicants, the effects of our preclinical and clinical activities, our ability to execute advertising strategies, our ability to expand our product. applicants with collaborative partners and the good fortune of those collaborations, the timing and duration of our product applicants’ progress toward clinical progression, the timing or likelihood of regulatory submissions and approvals, the good fortune of our advertising efforts to our product applicants if approved, our ability to manufacture and obtain our product applicants for clinical activities and for advertising use if approved, the extent of coverage that we can identify and maintain for intellectual asset rights covering our platform of generation. Our ability to unload financing, market and others in the long term. situations and those known in our annual report on Form 10-K and our upcoming quarterly reports on Form 10-Q. under the heading “Risk Factors” and in other documents filed through the Company from time to time with the SEC. Readers are cautioned to keep these threats in mind and not to rely on forward-looking statements, as actual effects could differ from those reflected in our forward-looking statements. Phio undertakes no legal responsibility to update any forecast to reflect an update in its opinions, occasions or cases after the date of this communication, unless required by law.
Contact: P hio Pharmaceuticals Corp. ir@phiopharma. com
Contact RPMichael AdamsBridge View Mediaadams@bridgeviewmedia. com
To view the source edition of this press release, https://www. newsfilecorp. com/release/215533